↓ Skip to main content

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Overview of attention for article published in Trials, August 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 5,948)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
4 news outlets
twitter
140 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
Published in
Trials, August 2022
DOI 10.1186/s13063-022-06649-3
Pubmed ID
Authors

Anan Manomaipiboon, Kittisak Pholtawornkulchai, Sujaree Poopipatpab, Swangjit Suraamornkul, Jakravoot Maneerit, Wiroj Ruksakul, Uraporn Phumisantiphong, Thananda Trakarnvanich

Twitter Demographics

The data shown below were collected from the profiles of 140 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 8 33%
Other 2 8%
Student > Bachelor 2 8%
Researcher 1 4%
Lecturer 1 4%
Other 1 4%
Unknown 9 38%
Readers by discipline Count As %
Unspecified 8 33%
Medicine and Dentistry 3 13%
Business, Management and Accounting 2 8%
Unknown 11 46%

Attention Score in Context

This research output has an Altmetric Attention Score of 134. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2023.
All research outputs
#263,230
of 23,047,237 outputs
Outputs from Trials
#28
of 5,948 outputs
Outputs of similar age
#7,503
of 431,166 outputs
Outputs of similar age from Trials
#3
of 215 outputs
Altmetric has tracked 23,047,237 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,948 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,166 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 215 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.